{"id":8448,"date":"2024-04-17T05:23:44","date_gmt":"2024-04-17T05:23:44","guid":{"rendered":"https:\/\/economicherald.net\/?p=8448"},"modified":"2024-04-17T05:23:44","modified_gmt":"2024-04-17T05:23:44","slug":"neurotech-reports-positive-top-line-phase-1-2-rett-syndrome-clinical-trial-results","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=8448","title":{"rendered":"Neurotech reports positive top-line Phase 1\/2 Rett Syndrome clinical trial results"},"content":{"rendered":"

Neurotech\u2019s NTIRTT1 becomes first clinical trial to show statistically significant clinical improvement in Rett Syndrome patients with a broad-spectrum cannabinoid drug
\nCompany\u2019s NTI164 compares favourably to DAYBUE, the only FDA-approved drug for Rett Syndrome
\nThird neurological disorder in children where NTI164 has shown a statistically significant clinical benefit, alongside autism and PANDAS\/PANS<\/p>\n

\u00a0<\/p>\n

Special Report: Neurotech International has reported positive top-line Phase 1\/2 Rett Syndrome clinical trial results with its NTI164 being the first broad-spectrum cannabinoid drug therapy to show a statistically significant clinical improvement in Rett Syndrome patients. <\/strong><\/p>\n

Clinical-stage biotech Neurotech International (ASX:NTI)\u00a0<\/strong><\/a>has reached a milestone, reporting the initial findings of its Phase 1\/2 clinical trial (NTIRTT1), showcasing the efficacy and safety outcomes of NTI164 in treating Rett Syndrome, the treatment of which is a US$2bn market.<\/p>\n

The trial involved 14 female paediatric patients who underwent a 12-week daily oral treatment regimen with NTI164.<\/p>\n

Results indicate a statistically significant improvement in Clinical Global Impression<\/p>\n

(CGI) scores, a key measure of clinical symptoms associated with Rett Syndrome, compared to baseline measures.<\/p>\n

The CGI scale is a tool used by clinicians to assess the overall state of an individual, commonly used in clinical trials for neuropsychiatric disorders.<\/p>\n

CGI-Improvement (CGI-I) is a component of this scale, employing a 7-point rating system to gauge the degree of improvement or worsening of a patient\u2019s condition compared to a baseline state.<\/p>\n

Initial primary endpoint analysis has shown a statistically significant improvement in CGI-1 at 12 weeks versus baseline measures with a mean difference of -0.3 (p=0.04). A decrease in CGI-I score indicates improvement.<\/p>\n

NTI\u2019s latest results demonstrate Rett Syndrome is the third neurological disorder in children where NTI164 has shown a statistically significant clinical benefit, alongside autism and PANDAS\/PANS.<\/p>\n

The company is focused predominately on paediatric neurological disorders.<\/p>\n

\u00a0<\/p>\n

Following in the footsteps of Neuren<\/strong><\/h2>\n

NTI is following in the footsteps of Neuren Pharmaceuticals (ASX:NEU)<\/strong><\/a> which became the 2023 ASX biotech market darling after its large pharma partner Acadia (NASDAQ:ACAD)<\/strong> announced that the US FDA had approved trofinetide for the treatment of Rett syndrome.<\/p>\n

Now dubbed DAYBUE, trofinetide is the first approved treatment for Rett syndrome with its official launch in the US by Acadia in April 2023 sending NEU\u2019s share price soaring.<\/p>\n

NTI says in the Phase 3 trial called LAVENDAR of trofinetide CGI-I served as a co-primary endpoint.<\/p>\n

Results showed a CGI-I improvement of -0.3 (8% improvement) in the trofinetide arm compared to placebo (p=0.003) with NTI164 comparing favourably to the only FDA-approved treatment.<\/p>\n

All 14 girls taking part in the trial will take part in the extended study of 52 weeks.<\/p>\n

\u00a0<\/p>\n

Need for more Rett treatments<\/strong><\/h2>\n

NTI executive director Dr Thomas Duthy says Rett Syndrome is a rare genetic neurological and developmental disorder and is almost exclusively the result of a mutation or mutations in the methyl CpG binding protein 2 (MECP2) gene located on the X chromosome, which is required for normal brain development and function.<\/p>\n

Duthy says Rett Syndrome occurs almost exclusively in girls, with an incidence of one in 10,000 female live births with the prevalence ~15,000 girls and women in the US and 350,000 globally.<\/p>\n

He says the Rett Syndrome market is estimated at more than US$2bn annually.<\/p>\n

\u201cWe warmly congratulate our principal investigator Associate Professor Carolyn Ellaway and her Rett Syndrome patients and families who took part in the trial,\u201d he says.<\/p>\n

Ellaway is the senior staff specialist NSW Genetic Metabolic Disorders Service, the Sydney Children\u2019s Hospital Network and Metabolic Genetics at The Children\u2019s Hospital at Westmead.<\/p>\n

\u201cThere remains an urgent need for more safe and effective therapies in Rett Syndrome,\u201d Duthy said.<\/p>\n

\u201cData analysis and interpretation continues, and we are very much looking forward to finalising and reporting further detailed clinical findings over the next two to four weeks and thereafter presenting this data at a major scientific meeting.\u201d<\/p>\n

\u00a0<\/p>\n\n

\ufeff<\/span>\ufeff<\/span>\u00a0<\/p>\n

This article was developed in collaboration with Neurotech International, a Stockhead advertiser at the time of publishing. <\/em>\u00a0<\/em><\/p>\n

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.<\/em><\/p>\n

<\/span><\/p>\n

The post Neurotech reports positive top-line Phase 1\/2 Rett Syndrome clinical trial results<\/a> appeared first on Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

Neurotech\u2019s NTIRTT1 becomes first clinical trial to show statistically significant clinical improvement in Rett Syndrome patients with a broad-spectrum cannabinoid drug Company\u2019s NTI164 compares favourably [more…]<\/a><\/p>\n","protected":false},"author":0,"featured_media":8449,"comment_status":"","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-8448","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"\nNeurotech reports positive top-line Phase 1\/2 Rett Syndrome clinical trial results - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=8448\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neurotech reports positive top-line Phase 1\/2 Rett Syndrome clinical trial results - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Neurotech\u2019s NTIRTT1 becomes first clinical trial to show statistically significant clinical improvement in Rett Syndrome patients with a broad-spectrum cannabinoid drug Company\u2019s NTI164 compares favourably [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=8448\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-17T05:23:44+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8448#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8448\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Neurotech reports positive top-line Phase 1\\\/2 Rett Syndrome clinical trial results\",\"datePublished\":\"2024-04-17T05:23:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8448\"},\"wordCount\":694,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8448#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/NEU-Rett-zvOGaK.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8448\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=8448\",\"name\":\"Neurotech reports positive top-line Phase 1\\\/2 Rett Syndrome clinical trial results - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8448#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8448#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/NEU-Rett-zvOGaK.jpeg\",\"datePublished\":\"2024-04-17T05:23:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8448#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=8448\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8448#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/NEU-Rett-zvOGaK.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/NEU-Rett-zvOGaK.jpeg\",\"width\":2121,\"height\":1193},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=8448#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neurotech reports positive top-line Phase 1\\\/2 Rett Syndrome clinical trial results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neurotech reports positive top-line Phase 1\/2 Rett Syndrome clinical trial results - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=8448","og_locale":"en_US","og_type":"article","og_title":"Neurotech reports positive top-line Phase 1\/2 Rett Syndrome clinical trial results - Economic Herald","og_description":"Neurotech\u2019s NTIRTT1 becomes first clinical trial to show statistically significant clinical improvement in Rett Syndrome patients with a broad-spectrum cannabinoid drug Company\u2019s NTI164 compares favourably [more...]","og_url":"https:\/\/economicherald.net\/?p=8448","og_site_name":"Economic Herald","article_published_time":"2024-04-17T05:23:44+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=8448#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=8448"},"author":{"name":"","@id":""},"headline":"Neurotech reports positive top-line Phase 1\/2 Rett Syndrome clinical trial results","datePublished":"2024-04-17T05:23:44+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=8448"},"wordCount":694,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=8448#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/04\/NEU-Rett-zvOGaK.jpeg","articleSection":["Finance"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=8448","url":"https:\/\/economicherald.net\/?p=8448","name":"Neurotech reports positive top-line Phase 1\/2 Rett Syndrome clinical trial results - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=8448#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=8448#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/04\/NEU-Rett-zvOGaK.jpeg","datePublished":"2024-04-17T05:23:44+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=8448#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=8448"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=8448#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/04\/NEU-Rett-zvOGaK.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/04\/NEU-Rett-zvOGaK.jpeg","width":2121,"height":1193},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=8448#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"Neurotech reports positive top-line Phase 1\/2 Rett Syndrome clinical trial results"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/8448","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8448"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/8448\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/8449"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8448"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8448"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8448"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}